Aurinia sees another way forward for voclosporin
Aurinia's lead project shows promise in its back-up use of dry eye, but risks distracting the company from a late-stage lupus trial.
Gene therapy: how much will it cost patients?
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
Big caps provide a safe haven
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
Go or no go? Roche, Jazz and Camarus await crucial regulatory readouts
The final month of 2018 will see FDA verdicts on Roche’s bid to play in the first-line lung cancer space, and what Jazz hopes will be its next big narcolepsy product.
Novel drug approvals set to hit a new record in 2018
Amid market volatility, biotech’s best friend comes through once again: the FDA has authorised a bumper 53 new medicines so far in 2018 and several more are expected…
Something seems to work in Alzheimer’s – and it’s more blood than brain
Grifols has announced intriguing results in a subgroup of patients in a large Alzheimer's disease study, Ambar, but the finding could also benefit other suppliers of…
Cost-effectiveness doubts could hit Shire’s Takhzyro launch
A damning report by the US pricing watchdog Icer could bode ill for the uptake of Shire’s big hereditary angioedema hope.
Non-inhibitor Hemlibra approval means Roche now has to deliver
As the Roche drug secures its second, most valuable, green light the pressure is on the Swiss group to execute.
Attention deficit disorder focus turns to side effects
Limiting abuse and reducing risks are the differentiating factors for projects from Kempharm and Supernus.
